Article | March 31, 2020

Virtual Panel: Leveraging A Biomanufacturing Legacy To Support New Business

Grifols

The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and manufacturing experience is the foundation of the business today at Grifols Recombinant Protein Contract Development and Manufacturing Organization (CDMO).

Recently, Grifols expanded its focus to apply its expertise to producing therapeutic proteins for biopharmaceutical organizations. Its new GMP consolidated manufacturing facility (CMF) supports this expansion. The CMF facility houses multiproduct production and features state-of-the-art equipment, including a distributed control system and a central data historian. We sat down with seven diverse experts at Grifols Recombinant Protein CDMO to discuss how the group’s legacy and recent investments support its future in providing recombinant protein CDMO services.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

CHIRONĀ® Recombinant Proteins